Net Profit Margin
since 2005
Calculation
Eli Lilly & Co., net profit margin, long-term trends, calculation
| Net profit margin | = | 100 | × | Net income (loss)1 | ÷ | Revenue1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 31.67% | = | 100 | × | 20,640) | ÷ | 65,179) |
| Dec 31, 2024 | 23.51% | = | 100 | × | 10,590) | ÷ | 45,043) |
| Dec 31, 2023 | 15.36% | = | 100 | × | 5,240) | ÷ | 34,124) |
| Dec 31, 2022 | 21.88% | = | 100 | × | 6,245) | ÷ | 28,541) |
| Dec 31, 2021 | 19.71% | = | 100 | × | 5,582) | ÷ | 28,318) |
| Dec 31, 2020 | 25.24% | = | 100 | × | 6,194) | ÷ | 24,540) |
| Dec 31, 2019 | 37.27% | = | 100 | × | 8,318) | ÷ | 22,320) |
| Dec 31, 2018 | 13.16% | = | 100 | × | 3,232) | ÷ | 24,556) |
| Dec 31, 2017 | -0.89% | = | 100 | × | (204) | ÷ | 22,871) |
| Dec 31, 2016 | 12.90% | = | 100 | × | 2,738) | ÷ | 21,222) |
| Dec 31, 2015 | 12.07% | = | 100 | × | 2,408) | ÷ | 19,959) |
| Dec 31, 2014 | 12.19% | = | 100 | × | 2,391) | ÷ | 19,616) |
| Dec 31, 2013 | 20.27% | = | 100 | × | 4,685) | ÷ | 23,113) |
| Dec 31, 2012 | 18.09% | = | 100 | × | 4,089) | ÷ | 22,603) |
| Dec 31, 2011 | 17.90% | = | 100 | × | 4,348) | ÷ | 24,287) |
| Dec 31, 2010 | 21.97% | = | 100 | × | 5,070) | ÷ | 23,076) |
| Dec 31, 2009 | 19.82% | = | 100 | × | 4,329) | ÷ | 21,836) |
| Dec 31, 2008 | -10.17% | = | 100 | × | (2,072) | ÷ | 20,378) |
| Dec 31, 2007 | 15.85% | = | 100 | × | 2,953) | ÷ | 18,634) |
| Dec 31, 2006 | 16.97% | = | 100 | × | 2,663) | ÷ | 15,691) |
| Dec 31, 2005 | 13.52% | = | 100 | × | 1,980) | ÷ | 14,645) |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
The net profit margin exhibited considerable fluctuation between 2005 and 2025. Initial years demonstrated a generally positive trend, followed by a significant downturn, and then a period of substantial growth before stabilizing and increasing again in later years.
- Initial Growth & Volatility (2005-2008)
- From 2005 to 2007, the net profit margin increased from 13.52% to 15.85%, indicating improving profitability. However, 2008 saw a dramatic shift, with the margin plummeting to -10.17%, representing a net loss. This suggests a significant adverse event impacting profitability during that period.
- Recovery & Expansion (2009-2014)
- Following the loss in 2008, the net profit margin rebounded strongly, reaching 19.82% in 2009 and peaking at 21.97% in 2010. The margin remained relatively stable between approximately 17.90% and 20.27% from 2011 through 2013, before decreasing to 12.19% in 2014. This period indicates a successful recovery and sustained profitability.
- Moderate Performance & Significant Surge (2015-2019)
- The net profit margin hovered around 12% to 13% between 2015 and 2017, with a brief dip into negative territory (-0.89%) in 2017. A substantial increase occurred in 2018, with the margin jumping to 37.27%, followed by 25.24% in 2019. This suggests a major positive shift in the company’s financial performance, potentially driven by new products or cost reductions.
- Recent Trends & Peak (2020-2025)
- From 2020 to 2022, the net profit margin experienced a decline from 25.24% to 15.36%, although remaining positive. However, 2023 and 2024 witnessed a significant upward trend, reaching 23.51% and then a high of 31.67% respectively. The continued growth into 2025, reaching 31.67%, indicates sustained strong profitability and potentially increasing efficiency or market dominance.
Overall, the net profit margin demonstrates a cyclical pattern with periods of growth, decline, and recovery. The most recent trend indicates a strong and positive trajectory, suggesting improved financial health and operational effectiveness.
AI Ask an analyst for more
Comparison to Competitors
Eli Lilly & Co., net profit margin, long-term trends, comparison to competitors
| Eli Lilly & Co. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 31.67% | 6.91% | 21.94% | 14.64% | 14.71% | 29.43% | 28.46% | 28.08% | 12.42% | 31.41% | 15.05% | 32.94% |
| Dec 31, 2024 | 23.51% | 7.59% | 12.77% | -18.53% | 16.33% | 1.68% | 15.84% | 26.68% | 12.62% | 31.07% | 14.77% | -4.86% |
| Dec 31, 2023 | 15.36% | 8.95% | 24.96% | 17.83% | 19.94% | 21.03% | 41.28% | 0.61% | 3.56% | 30.14% | 13.99% | 36.68% |
| Dec 31, 2022 | 21.88% | 20.39% | 26.42% | 13.71% | 22.91% | 17.02% | 18.90% | 24.49% | 31.01% | 35.64% | 15.47% | 37.20% |
| Dec 31, 2021 | 19.71% | 20.54% | 24.25% | 15.08% | 21.84% | 23.05% | 22.26% | 26.79% | 26.76% | 50.25% | 19.70% | 30.92% |
| Dec 31, 2020 | 25.24% | 10.08% | 29.97% | -21.20% | 16.36% | 0.51% | 17.82% | 14.72% | 22.53% | 41.35% | 19.79% | 43.70% |
| Dec 31, 2019 | 37.27% | 23.69% | 35.32% | 13.15% | 16.80% | 24.35% | 18.42% | 21.01% | 31.45% | 26.91% | 14.47% | 28.27% |
| Dec 31, 2018 | 13.16% | 17.36% | 37.25% | 21.81% | 13.33% | 25.16% | 18.75% | 14.71% | 20.79% | 36.42% | 12.06% | 68.80% |
| Dec 31, 2017 | -0.89% | 18.82% | 9.08% | 4.85% | 13.60% | 18.03% | 1.70% | 5.97% | 40.55% | 20.41% | 10.64% | 10.59% |
| Dec 31, 2016 | 12.90% | 23.22% | 35.27% | 22.94% | 15.13% | 45.07% | 23.01% | 9.85% | 13.66% | 18.42% | 11.06% | -6.58% |
| Dec 31, 2015 | 12.07% | 22.50% | 33.13% | 9.45% | 16.33% | 56.32% | 21.99% | 11.25% | 14.25% | 15.50% | 11.64% | -53.89% |
| Dec 31, 2014 | 12.19% | 8.89% | 26.69% | 12.62% | 13.05% | 49.44% | 21.96% | 28.22% | 18.42% | 12.34% | 11.22% | -127.25% |
| Dec 31, 2013 | 20.27% | 21.97% | 27.93% | 15.64% | 14.10% | 28.46% | 19.40% | 10.00% | 42.65% | 20.16% | 9.73% | -36.72% |
| Dec 31, 2012 | 18.09% | 28.70% | 26.11% | 11.12% | 13.10% | 27.57% | 16.14% | 13.05% | 24.70% | 54.43% | 9.42% | -7.01% |
| Dec 31, 2011 | 17.90% | — | 24.08% | 17.46% | 13.50% | 34.60% | 14.87% | 13.05% | 14.84% | -49.74% | 11.34% | 2.10% |
| Dec 31, 2010 | 21.97% | — | 31.56% | 15.92% | 13.58% | 39.26% | 21.65% | 1.87% | 12.18% | -22.76% | 9.60% | -526.35% |
| Dec 31, 2009 | 19.82% | — | 32.09% | 56.42% | 10.30% | 40.74% | 19.82% | 47.04% | 17.27% | -17.88% | 8.41% | -630.27% |
| Dec 31, 2008 | -10.17% | — | 28.57% | 25.47% | 10.38% | 39.55% | 20.31% | 32.74% | 16.78% | -34.69% | 9.47% | -262.02% |
| Dec 31, 2007 | 15.85% | — | 22.12% | 11.19% | 12.42% | 43.27% | 17.31% | 13.54% | 16.82% | -84.46% | 7.81% | -196.61% |
| Dec 31, 2006 | 16.97% | — | 21.29% | 8.85% | 11.69% | -45.98% | 20.73% | 19.59% | 39.98% | -161.30% | 4.46% | -95.63% |
| Dec 31, 2005 | 13.52% | — | 30.56% | 15.62% | 11.24% | 44.99% | 20.61% | 21.04% | 15.76% | -144.19% | 8.48% | -126.43% |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Eli Lilly & Co., net profit margin, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Eli Lilly & Co. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2025 | 31.67% | 21.54% |
| Dec 31, 2024 | 23.51% | 12.30% |
| Dec 31, 2023 | 15.36% | 17.95% |
| Dec 31, 2022 | 21.88% | 22.55% |
| Dec 31, 2021 | 19.71% | 23.38% |
| Dec 31, 2020 | 25.24% | 14.07% |
| Dec 31, 2019 | 37.27% | 23.22% |
| Dec 31, 2018 | 13.16% | 19.82% |
| Dec 31, 2017 | -0.89% | 13.06% |
| Dec 31, 2016 | 12.90% | 20.78% |
| Dec 31, 2015 | 12.07% | 21.17% |
| Dec 31, 2014 | 12.19% | 21.24% |
| Dec 31, 2013 | 20.27% | 21.99% |
| Dec 31, 2012 | 18.09% | 18.53% |
| Dec 31, 2011 | 17.90% | 15.70% |
| Dec 31, 2010 | 21.97% | 15.16% |
| Dec 31, 2009 | 19.82% | 25.73% |
| Dec 31, 2008 | -10.17% | 18.17% |
| Dec 31, 2007 | 15.85% | 15.90% |
| Dec 31, 2006 | 16.97% | 22.24% |
| Dec 31, 2005 | 13.52% | 18.33% |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Eli Lilly & Co., net profit margin, long-term trends, comparison to industry (health care)
| Eli Lilly & Co. | Health Care | |
|---|---|---|
| Dec 31, 2025 | 31.67% | 11.79% |
| Dec 31, 2024 | 23.51% | 8.84% |
| Dec 31, 2023 | 15.36% | 11.49% |
| Dec 31, 2022 | 21.88% | 14.65% |
| Dec 31, 2021 | 19.71% | 15.24% |
| Dec 31, 2020 | 25.24% | 10.27% |
| Dec 31, 2019 | 37.27% | 14.56% |
| Dec 31, 2018 | 13.16% | 12.61% |
| Dec 31, 2017 | -0.89% | 9.26% |
| Dec 31, 2016 | 12.90% | 12.80% |
| Dec 31, 2015 | 12.07% | 13.94% |
| Dec 31, 2014 | 12.19% | 14.40% |
| Dec 31, 2013 | 20.27% | 15.04% |
| Dec 31, 2012 | 18.09% | 13.92% |
| Dec 31, 2011 | 17.90% | 12.06% |
| Dec 31, 2010 | 21.97% | 11.90% |
| Dec 31, 2009 | 19.82% | 17.77% |
| Dec 31, 2008 | -10.17% | 13.00% |
| Dec 31, 2007 | 15.85% | 12.52% |
| Dec 31, 2006 | 16.97% | 15.30% |
| Dec 31, 2005 | 13.52% | 14.61% |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).